In The News Posted March 22, 2019 Share Posted March 22, 2019 NEW YORK, March 22, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today the formation of the core investigator group to support clinical and regulatory pathways for a portfolio of... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.